Daraxonrasib nearly doubles median survival for advanced pancreatic cancer patients and offers better quality of life compared to chemotherapy. The oral drug targets KRAS mutations and is moving toward expedited FDA approval.
Daraxonrasib nearly doubles median survival for advanced pancreatic cancer patients and offers better quality of life compared to chemotherapy. The oral drug targets KRAS mutations and is moving toward expedited FDA approval.